Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enarodustat vs Yibi Bio in renal anemia due to diabetic nephropathy (Phase 4, China)
ChiCTR2500112051Phase 4Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of enarodustat in anemia of renal disease, diabetic glomerulosclerosis and chronic kidney disease (CKD) (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Hemoglobin (Hb). Planned start Nov 2025; status: not yet recruiting.
02
Drugs
enarodustat
03
Conditions
anemia of renal diseasediabetic glomerulosclerosischronic kidney disease (CKD)
Beyond the preview
Go deeper on ChiCTR2500112051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112051.